Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course

Nat Immunol. 2023 Apr;24(4):604-611. doi: 10.1038/s41590-023-01445-w. Epub 2023 Mar 6.


Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1 yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Autoantibodies
  • COVID-19*
  • Chemokines
  • Humans
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2


  • Autoantibodies
  • Chemokines